cancer immunotherapy

Pharma Adam Feuerstein

Is ‘STING’ a new and promising cancer target? Don’t look at Merck’s study results for a definitive answer

Adam's Take Adam Feuerstein

The investor euphoria for Incyte’s experimental cancer drug is hard to rationalize

Pharma Adam Feuerstein

AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients

Health Associated Press

Some immune-boosting cancer drugs may pose rare heart risks

Biotech Arlene Weintraub

A biotech firm, on the brink of ruin, resurrects itself via man — and microbe